反应详情

To a solution of 4-[({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino) carbonyl]benzoic acid (0.0452 g, 0.10 mmol) in DCM (1.0 mL) was added 1,1-dimethylethyl 4-{[5′-(aminomethyl)-2′-fluoro-3-biphenylyl]methyl}-1-piperazinecarboxylate (0.040 g, 0.10 mmol), HBTU (0.0569 g, 0.15 mmol), and Et3N (0.0281 mL, 0.20 mmol). This mixture was stirred at room temperature for 1 h, was concentrated and purified using a Gilson HPLC (with TFA). TFA (1 drop in each tube ˜12 mL) was added to Fractions containing product and solvent was concentrated using a GeneVav EZ-2 evaporator. The compound was purified again using a Gilson HPLC (with TFA) and evaporating the solvent using a GeneVav EZ-2 evaporator. Product was basified with an amine cartridge to afford 0.0284 g (39%) of the title compound. LC-MS m/z 733 (M+H)+; 1H-NMR (400 MHz, CD3OD) δ ppm 1.41 (t, J=7.65 Hz, 3 H) 1.49 (t, J=7.28 Hz, 3 H) 1.81-1.93 (m, 2 H) 2.06-2.14 (m, 2 H) 3.11-3.28 (m, 6 H) 3.39-3.46 (m, J=4.52 Hz, 4 H) 3.64-3.74 (m, 2 H) 4.01-4.10 (m, 2 H) 4.14-4.20 (m, 2 H) 4.32-4.42 (m, J=4.27, 4.27 Hz, 1 H) 4.47 (q, J=7.11 Hz, 2 H) 4.61 (s, 2 H) 4.70-4.76 (m, 2 H) 7.18 (dd, J=10.54, 8.53 Hz, 1 H) 7.37-7.43 (m, 1 H) 7.46-7.56 (m, 3 H) 7.58-7.63 (m, 1 H) 7.67 (s, 1 H) 7.93-8.01 (m, 4 H) 8.30 (s, 1 H).

1. concentrationwas concentrated
2. custompurified
3. additionTFA (1 drop in each tube ˜12 mL) was added to Fractions
4. additioncontaining product and solvent
5. concentrationwas concentrated
6. customa GeneVav EZ-2 evaporator
7. customThe compound was purified again
8. customevaporating the solvent
9. customa GeneVav EZ-2 evaporator